Regenerative Medicine Market

The regenerative medicine market is projected to reach USD 62.69 billion by 2031 from USD 23.90 billion in 2026, at a CAGR of 21.3% during the forecast period. The market growth is supported by expanding clinical adoption of cell and gene therapies, a growing pipeline of advanced therapies, and rising investment in regenerative treatment development. Advances in cell processing, manufacturing, smart biomaterials, injectable scaffolds, and AI-enabled therapy development are also expected to support market expansion.

The global regenerative medicine market is highly competitive, with multiple companies competing for high market shares. The prominent players operating in this market include Novartis AG (Switzerland), Gilead Sciences, Inc. (US), Bristol Myers Squibb (US), Sarepta Therapeutics, Inc. (US), and Biogen, Inc. (US), among others.

To know about the assumptions considered for the study download the pdf brochure

Sarepta Therapeutics, Inc.

Sarepta is a commercial-stage biopharmaceutical company focused on discovering, developing, and marketing unique RNA-targeted therapeutics to treat rare diseases. The company operates as a single business unit. The company focuses on offering precision genetic medicines, which are a part of the regenerative medicine market. Currently, the company has pipeline candidates focusing on Duchenne Muscular Dystrophy, Limb-Girdle Muscular Dystrophies, Charcot-Marie-Tooth Neuropathies, and Pompe disease.

Gilead Sciences, Inc. (US)

Gilead is a research-based biopharmaceutical company involved in developing, manufacturing, and marketing novel medicines. The company operates in a single business segment. Based on products, the company's revenue can be divided into HIV, HCV, HBV/ HDV, Cell Therapy, VELDURY, TRODELVY, and others. YESCARTA (axicabtagene ciloleucel) and TECARTUS (brexucabtagene autoleucel) are the FDA-approved regenerative medicine products offered by the company. These products are used for oncology indications. The major strengths of the company include a wide geographic reach and strong brand image. The company has a geographic presence across 35 countries, with a strong distribution network.

Bristol Myers Squibb (US)

Bristol Myers Squibb is a major participant in cell-based immunotherapy through its CAR-T portfolio, including BREYANZI and ABECMA. These therapies address multiple hematologic malignancies and support the company's broader oncology strategy. Bristol Myers Squibb is expanding its cell therapy position through additional indications, manufacturing scale-up, clinical research, and development of next-generation cellular platforms for patients with difficult-to-treat cancers.

Market Ranking

The regenerative medicine market has a mixed competitive structure, with large biopharmaceutical companies holding strong positions in commercial cell and gene therapies while specialized biotechnology companies lead several stem-cell and tissue engineering niches. Competitive positioning is influenced by clinical efficacy, breadth of approved indications, manufacturing reliability, treatment center access, reimbursement, and the ability to scale complex personalized and advanced therapies.

Gilead Sciences, Inc. (US), through Kite, maintains a broad CAR-T presence with YESCARTA and TECARTUS and continues to strengthen manufacturing and clinical development capabilities to support wider use of autologous cell therapies. Bristol Myers Squibb (US) has expanded its cell therapy franchise through BREYANZI and ABECMA, supported by indication expansion, manufacturing investments, and an active pipeline of next-generation hematology programs. Novartis AG (Switzerland) has a diversified regenerative medicine presence across gene and cell therapy, supported by products such as Zolgensma and Kymriah and a global commercialization network. 

The remainder of the market includes companies such as Vericel, MIMEDX, Organogenesis, MEDIPOST, JCR Pharmaceuticals, Mesoblast, and other regional and emerging developers. These players compete through differentiated gene therapies, stem cell products, tissue-engineered products, regenerative wound care solutions, targeted clinical indications, and partnerships that help expand manufacturing, regulatory access, and commercialization across global markets.

Related Reports:

Regenerative Medicine Market by Product (Stem Cell [Autologous, Allogeneic], Immunotherapy, Gene Therapy, Tissue Engineering), Application (Musculoskeletal, Cancer, Dermatology, CVD, Ophthalmology, Neurology), Region, Competition - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]